Nobel Prize for Medicine: US Duo Ambros and Ruvkun Win for MicroRNA Discovery
Nobel Prize for Medicine: US Duo Ambros and Ruvkun Win for MicroRNA Discovery
The Facts
On Monday, the Nobel Assembly at Karolinska Institute in Stockholm, Sweden, awarded US scientists Victor Ambros and Gary Ruvkun the 2024 Nobel Prize in Medicine for discovering microRNA and its essential role in multicellular organism growth and survival.On Monday, the Nobel Prize committee at the Karolinska Institute in Stockholm, Sweden, awarded US scientists Victor Ambros and Gary Ruvkun the 2024 Nobel Prize in Medicine for discovering microRNA and its essential role in multicellular organism growth and survival.
Ambros and Ruvkun originally studied genes that regulate genetic development to ensure cell type development. The panel concluded that their study “revealed a new dimension to gene regulation, essential for all complex life forms.”
The Spin
TheVictor mRNAAmbros vaccinesand haveGary beenRuvkun's aremarkable game-changerdiscovery inof themicroRNA fightearned againstthem COVID-19,this offeringyear's unprecedentedNobel protectionPrize andin helpingMedicine. toThey curbfound thea spreadnew class of thesmall virus.RNA Thismolecules technologythat hasplay thean potentialimportant tofunction revolutionizein vaccinegene developmentregulation. forThe othertwo diseases,scientists potentiallyhave savinguncovered countlessa livesnew inlevel theof future.understanding Thein rapidthe development and deploymentfunction of thesemulticellular vaccinesorganisms, showcaseincluding the power of scientific innovation in addressing global health criseshumans.
WhileThe mRNArecognition vaccinesof havemicroRNAs shownwith effectivenessthe against2024 COVID-19,Nobel concernsPrize havein beenMedicine raisedwas aboutan potentialunexpected sideyet effectswelcome development for some researchers, particularlygiven thethat riskmicroRNA oftherapies myocarditisremain in youngtheir menearly stages. The technologyNobel isCommittee stillawarded relativelythe newMedicine Prize in 2006 for the discovery of small interfering RNAs, andwhich long-termcontrol effectsgenes remainthrough unknown.an Morealternative researchmechanism, isfollowing neededthe identification of microRNAs. Researchers hope to fullyeventually understanduse thethese safetymaster profileregulators andfor potentialdisease applicationsdetection ofand mRNA-based therapiestreatment.
